William Blair Increases Earnings Estimates for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA) – Equities research analysts at William Blair lifted their Q1 2025 EPS estimates for Cabaletta Bio in a research report issued to clients and investors on Tuesday, April 1st. William Blair analyst S. Corwin now expects that the company will earn ($0.68) per share for the quarter, up from their previous estimate of ($0.72). The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. William Blair also issued estimates for Cabaletta Bio’s Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.72) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.82) EPS, Q4 2026 earnings at ($0.74) EPS and FY2026 earnings at ($2.91) EPS.

A number of other research firms also recently issued reports on CABA. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Cabaletta Bio in a research report on Tuesday. UBS Group dropped their price target on Cabaletta Bio from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday. Wells Fargo & Company reduced their target price on Cabaletta Bio from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Guggenheim reiterated a “buy” rating and set a $23.00 price target on shares of Cabaletta Bio in a report on Tuesday. Finally, Morgan Stanley reduced their price target on Cabaletta Bio from $30.00 to $22.00 and set an “overweight” rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $21.00.

Cabaletta Bio Stock Performance

NASDAQ:CABA opened at $1.11 on Friday. The stock has a fifty day moving average price of $1.98 and a two-hundred day moving average price of $2.89. The stock has a market capitalization of $56.32 million, a price-to-earnings ratio of -0.52 and a beta of 2.44. Cabaletta Bio has a 1 year low of $1.08 and a 1 year high of $19.04.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings data on Monday, March 31st. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.65).

Institutional Investors Weigh In On Cabaletta Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CABA. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Cabaletta Bio during the third quarter valued at about $32,000. Point72 DIFC Ltd acquired a new position in shares of Cabaletta Bio in the 3rd quarter valued at approximately $33,000. Intech Investment Management LLC purchased a new position in shares of Cabaletta Bio during the 3rd quarter valued at approximately $67,000. Miller Financial Services LLC acquired a new stake in shares of Cabaletta Bio during the fourth quarter worth approximately $33,000. Finally, Avanza Fonder AB bought a new stake in shares of Cabaletta Bio in the fourth quarter worth $40,000.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.